Connect public, paid and private patent data with Google Patents Public Datasets

Methods and compositions for topical wound treatment

Download PDF

Info

Publication number
US20040076671A1
US20040076671A1 US10367393 US36739303A US2004076671A1 US 20040076671 A1 US20040076671 A1 US 20040076671A1 US 10367393 US10367393 US 10367393 US 36739303 A US36739303 A US 36739303A US 2004076671 A1 US2004076671 A1 US 2004076671A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
wound
composition
lidocaine
dressing
invention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10367393
Inventor
Aletha Tippett
Original Assignee
Aletha Tippett
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/65Tetracyclines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Abstract

Compositions for improved treatment of wounds on a patient. A first composition having a safe and effective amount of lidocaine, wherein the composition is topically applied to a wound on a patient. A second composition having a safe and effective amount of lidocaine and a safe and effective amount of topical antibiotic, wherein the composition is topically applied to a wound on a patient. A method for treating a patient having a skin wound by locally administering a safe and effective amount of lidocaine and an antibiotic compound in the skin wound such that healing of the skin wound is enhanced.

Description

    RELATED APPLICATION
  • [0001]
    The present application claims priority under 35 U.S.C. § 19 of U.S. Provisional Application Serial No. 60/420008 filed Oct. 21, 2002.
  • TECHNICAL FIELD
  • [0002]
    The present invention relates generally to methods and compositions for treating patients, and more particularly to a method and composition for topical wound treatment.
  • BACKGROUND OF THE INVENTION
  • [0003]
    Wounds are commonplace from childhood to old age. Wounds are a significant problem among the geriatric and nursing home population, especially at the end of life. Pressure ulcers alone exact a -tremendous human and financial toll, costing on average more than $1,200 per patient per month to treat. The prevalence of pressure ulcers in 1997 was 16 of every 1,000 nursing home residents. A goal of a federal program, “Healthy People 2010” is a reduction of pressure ulcers to a prevalence of less than 8 per 1,000. Diabetic ulcers similarly result in significant morbidity and costs, with diabetics accounting for approximately 82,000 amputations annually in the U.S., averaging $30,000 per amputation. Other wounds plaguing the nursing home and end of life population are ulcers resulting from arterial and venous insufficiency, as well as traumatic wounds, and non-healing surgical wounds.
  • [0004]
    Most of the wounds treated are chronic wounds, often persisting for many months. Especially among the terminally ill, there is little expectation of healing a wound due to the population being malnourished, immobile and with many comorbidities that inhibit and delay wound healing. In addition, often the patient will not live long enough to heal a wound. In the terminally ill patient, the goal typically is palliation, including relief of pain, and prevention of infection. A chronic wound is any break, or ulceration, of the skin that is of long duration or recurs frequently and has not responded to conventional therapies.
  • [0005]
    Standard wound care involves debridement, cleansing and covering the wound with any of a variety of commercially available dressings. There are many special dressings available which are designed to keep wounds moist or absorb exudates. Some specialty dressings have silver impregnated in the dressing to prevent infection. Typically dressings are attached either with self-adhesive or tape, or in some cases are applied with a compression wrap. Recent high tech approaches are available for wound care using thermal wound treatments and vacuum pumps. While these can be effective, they are very expensive and healing times are still measured in weeks or months. As such, it is desired to have an inexpensive wound treatment method and composition which reduces the time required for wounds to heal.
  • SUMMARY OF THE INVENTION
  • [0006]
    Accordingly, it is an object of the present invention to provide novel methods and compositions for topical wound care which overcomes one or more disadvantages of the prior art.
  • [0007]
    It is a more specific object of the invention to provide novel methods and compositions for improved treatment of wounds on a patient utilizing lidocaine.
  • [0008]
    These additional objects and advantages are provided by the methods and compositions of improved treatment of wounds on a patient of the present invention.
  • [0009]
    More particularly, a method and composition are provided for improved treatment of wounds on a patient. The composition comprises a safe and effective amount of lidocaine in a carrier, wherein the composition is topically applied to a wound on a patient.
  • [0010]
    In another embodiment of the present invention, a composition for improved treatment of wounds on a patient is provided. The composition comprises a safe and effective amount of lidocaine in a carrier and a safe and effective amount of a topical antibiotic compound, wherein the composition is topically applied to a wound on a patient.
  • [0011]
    In another embodiment, the present invention is directed to a wound dressing comprising a bandage, a safe and effective amount of lidocaine in a carrier, wherein the wound dressing enhances healing of a wound.
  • [0012]
    Also provided is a method for treating a patient having a skin wound, including the steps of locally administering a safe and effective amount of lidocaine in a carrier to the skin wound such that the healing of the skin wound is enhanced.
  • [0013]
    Another aspect of the present invention is an article of manufacture comprising packaging material and a composition comprising a safe and effective amount of lidocaine in a carrier, wherein the packaging material comprises a label that indicates the composition is useful for treating a patient having a skin wound, and wherein local administration of the composition enhances healing of a skin wound.
  • [0014]
    Another aspect of the present invention is a method for treating a patient having a skin wound. The method includes the steps of applying a zinc oxide ointment around the external of the wound; applying lidocaine in a carrier to a dressing; applying the dressing to the wound; and securing the dressing to the patient.
  • [0015]
    Still other objects, advantages and novel features of the present invention will become apparent to those skilled in the art from the following detailed description, which is simply by way of illustration various modes contemplated for carrying out the invention. As will be realized, the invention is capable of other different obvious aspects, all without departing from the invention. Accordingly, the drawings and descriptions are illustrative in nature and not restrictive.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • [0016]
    While the specification concludes with claims particularly pointing out and distinctly claiming the present invention, it is believed the same will be better understood from the following description taken in conjunction with the accompanying drawings in which:
  • [0017]
    [0017]FIG. 1 is a schematic illustration of an exemplary wound care dressing according to an embodiment of the present invention;
  • [0018]
    [0018]FIG. 2 is a schematic illustration of a method of preparing an exemplary wound care dressing according to an embodiment of the present invention;
  • [0019]
    [0019]FIG. 3 is a schematic illustration of another exemplary wound care dressing according to an embodiment of the present invention;
  • [0020]
    [0020]FIGS. 4A and 4B are schematic illustrations of a method of securing an exemplary would care dressing according to an embodiment of the present invention;
  • [0021]
    [0021]FIG. 5 is a schematic illustration of another method of securing an exemplary wound care dressing according to an embodiment of the present invention;
  • [0022]
    [0022]FIG. 6 is a schematic illustration of another exemplary would care dressing according to an embodiment of the present invention;
  • [0023]
    [0023]FIG. 7 sets forth wound treatment performance of the present invention relating to exemplary case study one;
  • [0024]
    [0024]FIG. 8 sets forth wound treatment performance of the present invention relating to exemplary case study two; and
  • [0025]
    [0025]FIG. 9 sets forth wound treatment performance of the present invention relating to exemplary case study three.
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
  • [0026]
    Reference will now be made in detail to various embodiments of the invention, examples of which are illustrated in the accompanying drawings, wherein like numerals indicate similar elements throughout the views.
  • [0027]
    A novel wound care treatment has been developed which uses a composition comprising a safe and effective amount of lidocaine in a carrier, wherein the composition is topically applied to a wound on a patient. The phrase “safe and effective amount”, as used herein, means the amount of that component sufficient to significantly positively modify the condition to be treated, but low enough to avoid serious side effects (at a reasonable benefit/risk rational), within the scope of sound medical judgment. A safe and effective amount of the component will vary with the specific component which is employed, the ability of the composition to penetrate the component through the skin, the amount of the composition, the particular type of wound being treated, the age and physical condition of the patient being treated, the severity of the wound, the duration of the treatment, the nature of concurrent therapy, and like factors. In one exemplary embodiment, the lidocaine is viscous lidocaine. Other forms of lidocaine, such as injectable solution of lidocaine are also considered. The carrier may be any carrier known to one skilled in the art such as aqueous-based or oil-based carriers. Exemplary carriers include water and saline solution.
  • [0028]
    In an exemplary embodiment of the present invention, the composition comprises from about 5 mg to about 40 mg lidocaine hydrochloride per gram of the composition, more preferably from about 18 mg to about 25 mg lidocaine hydrochloride per gram of the composition and most preferably from about 18 mg to about 20 mg lidocaine hydrochloride per gram of the composition.
  • [0029]
    In one embodiment of the present invention, the composition further comprises a safe and effective amount of at least one topical antibiotic compound. The antibiotic compound is believed effective in preventing infection and may help promote healing. It is believed that there may be some theoretical inhibition of healing by lidocaine with subsequent increase in an infection and the addition of the antibiotic agent will counter that effect.
  • [0030]
    Exemplary topical antibiotic classes which may be employed include aminoglycosides, antifungals, carbapenems, cephalosporins, macrolides, penicillins, quinolones, sulfonamides, tetracyclines, chloramphenicol, clindamycin, metronidazole, nitrofurantoin, and vanomycin. Other classes of compounds which may be employed include antimalarials, antimycobacterials, antiparasitics, antiviral agents (such as anti-CMV, anti-herpetic, anti-HIV and anti-influenza) and dermatologic antibacterials (such as bacitracin, polymyxin, mafenide, mupirocin and silver sulfadiazine).
  • [0031]
    Exemplary topical antibiotic compounds which may be employed include chloramphenicol, chlortetracycline, clindamycin, erythromycin, gramicidin, gentamicin, metronidazole, mupiroicin, neomycin, polymyxin B, bacitracin, silver sulfadiazine, tetracycline, or combinations thereof. In addition, metronidazole is beneficial as the topical antibiotic, especially when odor of the wound is a problem. Crushed metronidazole tablets can be applied to the composition of the present invention.
  • [0032]
    In another exemplary embodiment of the present invention, the composition comprises from about 5 mg to about 40 mg lidocaine hydrochloride, about 250 units to about 2000 units polymyxin B sulfate and about 10 units to about 100 units bacitracin zinc per gram of the composition; and more preferably from about 18 mg to about 25 mg lidocaine hydrochloride, about 500 to about 1000 units polymyxin B sulfate and about 25 to about 50 units bacitracin zinc per gram of the composition.
  • [0033]
    In one exemplary embodiment of the present invention, the treatment method for treatment of a wound comprises debriding the wound, if necessary, and cleaning the wound with a suitable cleaning solution, such as normal saline. Thereafter, a zinc oxide ointment may be applied to the skin around the wound. It is believed that the ointment protects the surrounding skin, promotes healing and helps to hold the dressing in place. The substrate for the dressing may be one of any known to one skilled in the art. For example, exemplary substrates include gauze, foam, gels, and other conventional medical substrate dressings. Moreover, if the wound bed needs to be kept moist, the substrate can be moistened with normal saline. Alternatively, particularly if the wound bed has exudates, dry gauze or other absorbents can be used. In addition, if the wound bed is necrotic, the gauze may be moistened with one-quarter strength Dakins solution (hypochlorite, i.e., bleach) or an enzymatic debriding agent such as collagenase (Santyl®) may be added. The dressing is then layered with lidocaine and the antibiotic and applied to the wound.
  • [0034]
    After the dressing which is layered with the lidocaine and the topical antibiotic is applied to the wound, a top dressing such as gauze or bandage can be then applied to the patient to cover the wound and dressing. The top dressing may be taped, or wrapped in place depending on the patient's skin conditions and location of the wound. If the patient's skin is fragile it may be damaged by an adhesive. In this case, a top dressing of polymer film is applied and held in place by the zinc oxide ointment that surrounds the wound. Typically, the dressing is changed daily and as needed if soiled or disturbed.
  • [0035]
    The size and type of dressing used depends on the wound. In one exemplary embodiment, for a deep narrow wound which requires packing, gauze strips can be used. Shallow wounds can be dressed with simple two by two inch or four by four inch gauze pads. Deep large wounds can be packed with fluffed gauze pads. In all cases, the gauze is layered with lidocaine and the antibiotic compound.
  • [0036]
    [0036]FIG. 1 illustrates an exemplary embodiment of the present invention. A rectangular gauze pad 10 sized to fit the wound, is layered with viscous lidocaine 12 and a topical antibiotic powder 14 is sprinkled over the lidocaine layer. Enough viscous lidocaine 12 should be applied in a thin layer to cover an area the size of the wound.
  • [0037]
    Normal gauze pads are suitable for shallow wet or dry wounds. The gauze can be dry or moist, depending on the requirements of the wound bed. The gauze can be moistened with normal saline if needed for a dry wound bed. The dressing is then applied with the side of the gauze pad having the viscous lidocaine and antibiotic powder next to the wound.
  • [0038]
    In one embodiment, a zinc oxide barrier ointment is applied to the skin around the wound prior to application of the dressing. The zinc oxide barrier protects the skin from moisture and is believed to enhance healing as well as hold the dressing in place for attachment.
  • [0039]
    Wounds vary in size and may necessitate changing the gauze substrate in order to fill dead space in the wound. FIG. 2 illustrates gauze stripping 16 that can be pulled through a pool of viscous lidocaine 12 sprinkled with a topical antibiotic powder 14. The viscous lidocaine 12 can be poured into a small pool on a nonabsorbable surface and the topical antibiotic powder 14 can then be sprinkled over the lidocaine pool. The user can then pull the gauze strips through the pool using one hand to pull the strip and the other hand to push the strip into the pool of viscous lidocaine and topical antibiotic powder. The strip may then be packed into a deep narrow wound (such as those which often occur over the ischium).
  • [0040]
    In another embodiment, a rectangular gauze pad has the layers pulled apart to create a fluffy piece of gauze. FIG. 3 illustrates fluffed gauze 18 as the dressing. The viscous lidocaine 12 can be poured onto the fluffed gauze 18 and a topical antibiotic powder sprinkled over the viscous lidocaine on the fluffed gauze. This dressing may then be placed or packed in deep, larger wounds that require more volume to fill the wound bed than can be provided by a flat pad. Multiple fluffed pads can be used if needed to fill space in the wound. Other filling materials known to one skilled in the art may also be utilized instead of the fluffed gauze (e.g., cotton, alginates, hydrogels or cellulose).
  • [0041]
    The dressing containing the wound care composition may be attached to the patient using various methods known to one skilled in the art. For example, as depicted in FIGS. 4A and 4B, a rectangular pad dressing may be taped in place on the patient. The tape can be placed window pane style (4B) or corner taped (4A) using medical tapes known to those skilled in the art. One disadvantage of taping is potential damage to or allergic reaction on the patient's skin by the adhesive, or the tape not sticking to the patient. An alternative method of attachment is illustrated in FIG. 5. If the wound is on an extremity, such as foot or leg, the dressing can be held in place with gauze bandage 24 circumferentially wrapped. The gauze end is then anchored with a piece of tape 22 or clipped to the under layer of gauze. The advantage of this method is that the tape adhesive does not directly touch the skin. In one exemplary embodiment of the present invention, standard covers know to one skilled in the art may be utilized (e.g., Tegaderm® available from 3M and Opsite® available from Smith & Nephew).
  • [0042]
    Another exemplary method of attachment of the dressing to the patient is illustrated in FIG. 6. This embodiment utilizes a polymer film 28 (e.g., Saran Wrap® available from Dow Chemical or Reynolds® Plastic Wrap available from Reynolds Metals Company) to cover the dressing 20. When the polymer film is pressed against the zinc oxide ointment 26 around the wound, the polymer film is held securely in place. The zinc oxide ointment acts as a quasi gasket.
  • [0043]
    In another exemplary embodiment of the present invention, the composition for improved treatment of wounds on a patient further comprises a wax matrix. The wax matrix may be utilized in place of a dressing. Exemplary wax matrices include Bag Balm® available from Dairy Association Co. of Lyndonville, Vt., diaper rash ointment, Dermagran® available from Derma Sciences, vegetable shortening, petroleum jelly and zinc oxide ointment. One preferred wax matrix comprises a 40% (by weight) zinc oxide ointment.
  • [0044]
    In one embodiment, the composition further comprises a disinfectant compound to disinfect and dry a wound such as Dakin's solution (dilute hyperchloride or bleach). If odor control is desired, oil of wintergreen or other odor control agents can be added to the composition.
  • [0045]
    In another exemplary embodiment, the composition further comprises one or more enzymes for debridement such as collagenase (Santyl® available from Smith & Nephew), Accuzyme® and Panafil® both which are available from HealthPoint.
  • [0046]
    Another embodiment of the present invention comprises a wound dressing comprising a bandage, and a safe and effective amount of lidocaine in a carrier, wherein the wound dressing enhances healing of the wound. In an exemplary embodiment, the bandage comprises cotton, gauze, fiberglass or a synthetic material.
  • [0047]
    Another aspect of the present invention is a method for treating a patient having a skin wound. The method comprises locally administering a safe and effective amount of lidocaine in a carrier to the skin wound, such that the healing of the wound is enhanced. In one exemplary embodiment, the method further comprises covering the lidocaine composition in the skin wound with a dressing.
  • [0048]
    Yet another aspect of the present invention is an article of manufacture comprising packaging material and a composition comprising a safe and effective amount of lidocaine in a carrier, wherein the packaging material comprises a label that indicates the composition is useful for treating a patient having a skin wound, and wherein local administration of the composition enhances healing of the skin wound.
  • [0049]
    Another embodiment of the present invention is a pre-packaged wound dressing contained in a package, comprising a safe and effective amount of lidocaine in a carrier, and a bandage configured to cover a wound. In an exemplary embodiment, the lidocaine in the carrier is contained in a storage container. In another exemplary embodiment, the bandage is coated on at least one side with the lidocaine in the carrier. In another exemplary embodiment, the wound dressing is configured to deliver a controlled release of the composition to the wound bed at a predetermined rate for a predetermined time.
  • [0050]
    Another aspect of the present invention is a method for treating a patient having a skin wound comprising applying a mixture of lidocaine and a wax matrix directly on the wound. In one exemplary embodiment, the method further comprises applying a topical antibiotic powder on the lidocaine composition on the wound. In another exemplary embodiment, a polymer film is placed over composition on the wound bed and the composition is utilized to secure the polymer film to the patient.
  • EXAMPLE CASE STUDIES
  • [0051]
    Case One
  • [0052]
    A 91 year old white male hospice patient with end stage dementia. Wound on gluteal cleft had been worsening under prior treatment of Collagenase (Santyl®) and Polysporin® ointment (bacitracin zinc-polymyxin B). Prior to treatment with the method and composition of the present invention, the wound measured 4.5 cm3 and was tender. Treatment consisted of initially packing gauze strips coated with 2% viscous lidocaine in the wound bed. After wound had reduced in size to prevent packing (23 days after initial treatment), dressing containing 2% viscous lidocaine was applied to wound. FIG. 7 depicts the results of treatment of the gluteal wound. As can be seen from astonishing results depicted in FIG. 7, the gluteal cleft wound was unexpectedly reduced in size by approximately 85% in 23 days and completely healed in less than 80 days utilizing the present invention.
  • [0053]
    Case Two
  • [0054]
    A 86 year old white male with end stage renal disease and peripheral vascular disease had multiple non-healing wounds on the right leg. A heel wound had been surgically debrided and was non-healing. A traumatic injury to the right shin was non-healing. under prior treatment with Dakin's solution. Table 1 depicts the wounds and area size. Treatment utilized the present invention composition and method of a 2% viscous lidocaine solution with bacitracin zinc-polymyxin B powder. The composition comprised approximately 18-19.8 mg of lidocaine hydrochloride, 500-1000 units polymyxin B sulfate and 25-50 units of bacitracin zinc. The unexpected and astonishing results of the present invention are depicted in FIG. 8 which illustrates the amazing reduction in wound area on prior non-healing wounds.
    TABLE 1
    Wound Area (cm2) during treatment by number of months
    Before
    treatment
    utilizing
    Wound present 2 4 5 5.5 6 7 8
    location invention months* months months months months** months months
    Shin 15.75 24 16 12 10.0 12 4.4 0
    (closed)
    Lateral 5.5 14 1 <1 0 0 0 0
    mall (closed)
    heel 22.75 9 0 0 0 0 0 0
    (closed)
    lateral 3.94 7.5 2.4 0 0 0 0 0
    foot (closed)
    medial 0.375 .25 0 0 0 0 0 0
    dorsum (closed)
  • [0055]
    Case Three
  • [0056]
    A 40 year old white female hospice patient with end stage multiple sclerosis had a coccyx wound as well as multiple foot and leg wounds. Prior to treatment utilizing the present invention, the patient had 12 wounds with the coccyx wound having a surface area totaling 48 cm2. Treatment utilized the composition and method of the present invention: a 2% viscous lidocaine solution with bacitracin zinc-polymyxin B powder. The composition comprised approximately 18-19.8 mg of lidocaine hydrochloride, 500-1000 units polymyxin B sulfate and 25-50 units of bacitracin zinc per gram of the composition. The unexpected and astonishing results of the present invention are depicted in FIG. 9 which illustrates the amazing reduction in wound volume with complete healing in under 60 days.
  • [0057]
    These case studies demonstrate that the compositions and methods according to the present invention exhibit surprising results in the mitigation or elimination of non-healing wounds on patients.
  • [0058]
    The foregoing description of the various embodiments of the invention has been presented for the purposes of illustration and description. It is not intended to be exhaustive or to limit the invention to the precise form disclosed. Many alternatives, modifications and variations will be apparent to those skilled in the art of the above teaching. Accordingly, this invention is intended to brace all alternatives, modifications and variations that have been discussed herein, and others that fall within the spirit and broad scope of the claims.

Claims (32)

What is claimed:
1. A composition for use in the treatment of wounds, comprising a safe and effective amount of lidocaine in a carrier, wherein the composition is topically applied to a wound on a patient.
2. The composition of claim 1, wherein the lidocaine comprises viscous lidocaine.
3. The composition of claim 1, further comprising a safe and effective amount of a topical antibiotic compound.
4. The composition of claim 3, wherein the topical antibiotic comprises chloramphenicol, chlortetracycline, clindamycin, erythromycin, gramicidin, gentamicin, metronidazole, mupiroicin, neomycin, polymyxin B, bacitracin, silver sulfadiazine, tetracycline, chlortetracycline, or combinations thereof.
5. The composition of claim 3, wherein the topical antibiotic is polymyxin B sulfate.
6. The composition of claim 3, wherein the topical antibiotic is polymyxin B sulfate and bacitracin zinc.
7. The composition of claim 1, comprising from about 5 mg to about 40 mg lidocaine hydrochloride per gram of the composition.
8. The composition of claim 1, further comprising a wax matrix.
9. The composition of claim 8, wherein the wax matrix comprises Bag Balm®.
10. The composition of claim 8, wherein the wax matrix comprises zinc oxide ointment.
11. The composition of claim 3, comprising from about 5 mg to about 40 mg lidocaine hydrochloride and about 250 units to about 2000 units polymyxin B sulfate and about 10 units to about 100 units bacitracin zinc per gram of the composition.
12. The composition of claim 1, further comprising oil of wintergreen.
13. The composition of claim 1, further comprising one or more enzymes for debridement.
14. A wound dressing comprising a bandage, a safe and effective amount of lidocaine in a carrier, wherein the wound dressing enhances healing of a wound.
15. The wound dressing of claim 14, wherein the bandage comprises cotton, gauze, fiberglass or synthetic material.
16. The wound dressing of claim 14, further comprising a safe and effective amount of a topical antibiotic compound.
17. The wound dressing of claim 14, further comprising saline.
18. The wound dressing of claim 14, further comprising a disinfectant component.
19. A method for treating a patient having a skin wound, comprising locally administering a safe and effective amount of lidocaine in a carrier to the skin wound such that the healing of the skin wound is enhanced.
20. The method of claim 19, further comprising locally administering a safe and effective amount of a topical antibiotic compound to the skin wound.
21. The method of claim 20, further comprising covering the lidocaine and antibiotic compound in the skin wound with a dressing.
22. The method of claim 21, wherein the dressing comprises cotton, gauze, fiberglass or synthetic material.
23. The method of claim 21, wherein the dressing comprises a polymeric film.
24. An article of manufacture comprising packaging material and a composition comprising a safe and effective amount of lidocaine in a carrier, wherein the packaging material comprises a label that indicates the composition is useful for treating a patient having a skin wound, and wherein local administration of the composition enhances healing of a skin wound.
25. The article of manufacture of claim 24, wherein the composition further comprises a safe and effective amount of a topical antibiotic compound.
26. A pre-packaged wound dressing contained in a package, comprising:
a safe and effective amount of lidocaine in a carrier;
a safe and effective amount of a topical antibiotic compound; and
a bandage configured to cover a wound.
27. The pre-packaged wound dressing of claim 26, wherein the lidocaine and the antibiotic compound are contained in a storage container.
28. The pre-packaged wound dressing of claim 26, wherein the bandage is coated on at least one side with the lidocaine and the antibiotic compound.
29. A method for treating a patient having a skin wound, comprising:
applying a zinc oxide ointment around the exterior of the wound;
applying lidocaine and an antibiotic compound to a dressing;
applying the dressing to the wound; and
securing the dressing to the patient.
30. The method of claim 29, further comprising placing a packing material containing lidocaine and an antibiotic compound directly in the wound.
31. The method of claim 29, wherein securing the dressing comprises placing a polymer film over the dressing and utilizing the zinc oxide ointment surrounding the exterior of the wound to secure the polymer film to the patient.
32. The method of claim 29, further comprising applying a saline solution to the dressing if the wound is dry.
US10367393 2002-10-21 2003-02-14 Methods and compositions for topical wound treatment Abandoned US20040076671A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US42000802 true 2002-10-21 2002-10-21
US10367393 US20040076671A1 (en) 2002-10-21 2003-02-14 Methods and compositions for topical wound treatment

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10367393 US20040076671A1 (en) 2002-10-21 2003-02-14 Methods and compositions for topical wound treatment
US11619895 US20070110797A1 (en) 2002-10-21 2007-01-04 Methods and Compositions For Topical Wound Treatment
US11619903 US7728188B2 (en) 2002-10-21 2007-01-04 Methods and compositions for topical wound treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11619903 Division US7728188B2 (en) 2002-10-21 2007-01-04 Methods and compositions for topical wound treatment

Publications (1)

Publication Number Publication Date
US20040076671A1 true true US20040076671A1 (en) 2004-04-22

Family

ID=32095796

Family Applications (3)

Application Number Title Priority Date Filing Date
US10367393 Abandoned US20040076671A1 (en) 2002-10-21 2003-02-14 Methods and compositions for topical wound treatment
US11619895 Abandoned US20070110797A1 (en) 2002-10-21 2007-01-04 Methods and Compositions For Topical Wound Treatment
US11619903 Active 2024-02-20 US7728188B2 (en) 2002-10-21 2007-01-04 Methods and compositions for topical wound treatment

Family Applications After (2)

Application Number Title Priority Date Filing Date
US11619895 Abandoned US20070110797A1 (en) 2002-10-21 2007-01-04 Methods and Compositions For Topical Wound Treatment
US11619903 Active 2024-02-20 US7728188B2 (en) 2002-10-21 2007-01-04 Methods and compositions for topical wound treatment

Country Status (1)

Country Link
US (3) US20040076671A1 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050159477A1 (en) * 2002-07-25 2005-07-21 Chemagis Ltd Stable amorphous calcium pseudomonate and processes for the preparation thereof
US20070213688A1 (en) * 2003-05-21 2007-09-13 Klein Jeffrey A Infiltration cannula
US20080206371A1 (en) * 2007-02-22 2008-08-28 Healing Skin Llc Novel burn treatment composition
WO2009027823A2 (en) * 2007-08-29 2009-03-05 Ramirez D'onofrio, Alvaro D. Pharmaceutical composition for selective stimulation of wound healing processes, dermal-epidermal normal tissular trophism processes, its preparation and application.
WO2010013204A1 (en) * 2008-07-29 2010-02-04 Luisa Gennero Composition for regenerating senescent cutaneous and sub-cutaneous tissue, products and uses thereof
US20100233271A1 (en) * 2007-11-07 2010-09-16 Sawan Samuel P Slow release of organic salts of local anesthetics for pain relief
US20110091538A1 (en) * 2008-06-17 2011-04-21 Z.H.T. Engineering Equipment And Technologies Ltd. Polymer adapted to release bioactive agents in vivo, pharmaceutical composition and method of preparation thereof
US20140065119A1 (en) * 2010-11-10 2014-03-06 The University Of Western Ontario Methods and compositions comprising cyclic analogues of histatin 5 for treating wounds
US8957060B2 (en) 2009-11-30 2015-02-17 Jeffrey Alan KLEIN Tumescent antibiotic solution
US9592280B2 (en) * 2014-10-10 2017-03-14 Rochal Industries Llc Compositions and kits for enzymatic debridement and methods of using the same
EP3164139A4 (en) * 2014-07-01 2017-05-10 Enrique Chacon Topical compositions and methods for treating wounds
RU2641095C1 (en) * 2017-04-11 2018-01-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации Agent for pyoinflammatory processes in soft tissues and mucous membranes

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2708229A4 (en) 2011-05-10 2014-11-19 Itochu Chemical Frontier Corp Non-aqueous patch

Citations (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372786B1 (en) *
US3968205A (en) * 1974-01-31 1976-07-06 J. Pfrimmer And Co. Infusion solution for the treatment of tachycardiac disturbances of heart rhythm and use thereof
US4005191A (en) * 1974-06-04 1977-01-25 Clark Mary G Topical ointment composition
US4069105A (en) * 1977-03-03 1978-01-17 Syva Company Lidocaine antigens and antibodies
US4181725A (en) * 1977-05-02 1980-01-01 The Regents Of The University Of Michigan Method for alleviating psoriasis
US4210670A (en) * 1977-07-06 1980-07-01 Astra Lakemedel Aktiebolag Antithrombotic agents
US4529601A (en) * 1977-12-01 1985-07-16 Astra Lakemedel Aktiebolag Local anesthetic mixture for topical application and method for obtaining local anesthesia
US4588744A (en) * 1978-09-19 1986-05-13 Mchugh John E Method of forming an aqueous solution of 3-3-Bis(p-hydroxyphenyl)-phthalide
US4618490A (en) * 1980-06-06 1986-10-21 Marco Peter T De Method of treatment of animal and human tissues damaged by burns and frank visible gangrene
US4622219A (en) * 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
US4623334A (en) * 1983-03-07 1986-11-18 Vanderbilt University Intravenous drug infusion apparatus
US4628063A (en) * 1984-03-08 1986-12-09 Dana P. Brigham Antiviral pharmaceutical preparations and methods for their use
US4650771A (en) * 1983-11-04 1987-03-17 Miles Laboratories, Inc. Immunogens, antibodies, labeled conjugates, and related derivatives for lidocaine and analogs thereof
US4711906A (en) * 1984-12-21 1987-12-08 Merckle Gmbh Liquid diclofenac preparations
US4725442A (en) * 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US4748022A (en) * 1985-03-25 1988-05-31 Busciglio John A Topical composition
US4851442A (en) * 1986-02-12 1989-07-25 W. Keith R. Watson Lidocaine hydrochloride, citric acid and dimethyl sulfoxide, solution, and formation thereof
US4866050A (en) * 1988-04-27 1989-09-12 Ben Amoz Daniel Ultrasonic transdermal application of steroid compositions
US4891386A (en) * 1980-08-08 1990-01-02 Molteni & C. Dei F.Lli Alitti S.P.A. Lidocaine derivative and therapeutic compositions which contain it as principal active ingredient
US4914131A (en) * 1984-03-08 1990-04-03 Dana P. Brigham Antiviral pharmaceutical preparations and methods for their use
US4938970A (en) * 1987-02-06 1990-07-03 Hustead Robert E Painless electrolyte solutions
US4963591A (en) * 1985-12-16 1990-10-16 Carter-Wallace Inc. Cosmetic compositions
US4997853A (en) * 1988-12-02 1991-03-05 Galenpharma, Inc. Method and compositions utilizing capsaicin as an external analgesic
US5081157A (en) * 1988-05-02 1992-01-14 Zila Pharmaceuticals, Inc. Compositions and in situ methods for forming films on body tissue
US5112620A (en) * 1990-09-20 1992-05-12 Mikkur, Inc. Polyethylene glycol ointment for apthous ulcers
US5227165A (en) * 1989-11-13 1993-07-13 Nova Pharmaceutical Corporation Liposphere delivery systems for local anesthetics
US5290775A (en) * 1990-12-19 1994-03-01 Board Of Trustees Operating Michigan State University Euthanasia compositions
US5298528A (en) * 1991-10-07 1994-03-29 Baker Cummins Dermatologicals, Inc. Insect repellent
US5331013A (en) * 1989-06-08 1994-07-19 Aktiebolaget Astra Method for the treatment of ulcerative proctitis and colitis
US5331012A (en) * 1990-07-30 1994-07-19 Riddick Kenneth B Topical pharmaceutical preparation for fever blisters and other viral infections and method of use
US5330452A (en) * 1993-06-01 1994-07-19 Zook Gerald P Topical medicating device
US5387419A (en) * 1988-03-31 1995-02-07 The University Of Michigan System for controlled release of antiarrhythmic agents
US5405376A (en) * 1993-08-27 1995-04-11 Medtronic, Inc. Method and apparatus for ablation
US5411738A (en) * 1989-03-17 1995-05-02 Hind Health Care, Inc. Method for treating nerve injury pain associated with shingles (herpes-zoster and post-herpetic neuralgia) by topical application of lidocaine
US5415866A (en) * 1993-07-12 1995-05-16 Zook; Gerald P. Topical drug delivery system
US5417671A (en) * 1990-05-23 1995-05-23 Jackson; Richard R. Medical devices having local anesthetic effect and methods of their manufacture
US5420124A (en) * 1994-01-12 1995-05-30 Kim; Young S. Stable, painless piroxicam potassium injectable composition
US5453445A (en) * 1994-05-02 1995-09-26 Henry; Richard A. Lidocaine-phenylephrine aerosol preparation
US5480658A (en) * 1993-07-23 1996-01-02 Melman; Steven A. Ear and skin cleanser
US5504116A (en) * 1994-05-26 1996-04-02 Research Foundation Of State University Of New York Lidocaine for the management of preterm labor
US5510339A (en) * 1993-02-02 1996-04-23 Mayo Foundation For Medical Education And Research Method for the treatment of bronchial asthma by administration of topical anesthetics
US5516808A (en) * 1994-10-27 1996-05-14 Sawaya; Assad S. Topical cellulose pharmaceutical formulation
US5534242A (en) * 1994-05-02 1996-07-09 Henry; Richard A. Lidocaine-vasoconstrictor aerosol preparation
US5540669A (en) * 1993-09-30 1996-07-30 Becton, Dickinson And Company Iontophoretic drug delivery system and method for using same
US5558914A (en) * 1994-04-11 1996-09-24 Water-Jel Technologies, Inc. Water-based formulation for the treatment of sunburn
US5585398A (en) * 1994-07-15 1996-12-17 Ernst; Amy A. Topical anesthetic comprising lidocaine, adrenaline, and tetracaine, and its method of use
US5589156A (en) * 1994-05-02 1996-12-31 Henry; Richard A. Prilocaine and hydrofluourocarbon aerosol preparations
US5593661A (en) * 1993-03-29 1997-01-14 Henry; Richard A. Lidocaine aerosol anaesthetic
US5601838A (en) * 1989-03-17 1997-02-11 Hind Health Care, Inc. Method for treating pain associated with herpes-zoster and post-herpetic neuralgia
US5630843A (en) * 1994-06-30 1997-05-20 Rosenberg; Paul H. Double chamber tissue expander
US5698227A (en) * 1996-07-23 1997-12-16 Rivlin; Daniel Compositions comprising lidocaine and emu oil and methods of use thereof
US5707645A (en) * 1996-09-10 1998-01-13 Wierson; Mark Hemorrhoidal ice-treatment device
US5714165A (en) * 1990-09-20 1998-02-03 Mikkur, Inc. Bioadhesive polyethylene glycol ointment for medicaments
US5762945A (en) * 1996-04-05 1998-06-09 Ashley; Eline Composition and method for treating diaper rash
US5762063A (en) * 1997-05-21 1998-06-09 Coates; Michael R. Bag-valve-mask resuscitator attachment having syringe and nebulizer injection ports
US5827529A (en) * 1991-03-30 1998-10-27 Teikoku Seiyaku Kabushiki Kaisha External preparation for application to the skin containing lidocaine
US5837713A (en) * 1997-02-26 1998-11-17 Mayo Foundation For Medical Education And Research Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids
US5891919A (en) * 1997-09-19 1999-04-06 Burlington Bio-Medical & Scientific Corp. Denatonium capsaicinate and methods of producing the same
US5898035A (en) * 1995-08-29 1999-04-27 New York Medical College Formulations of haloalkylamines and local anesthetic and methods for the treatment of reflex sympathetic dystrophy (RSD)
US5955112A (en) * 1998-02-11 1999-09-21 Kaplan; Jeffrey Non-stinging styptic pencil
US5961997A (en) * 1997-03-25 1999-10-05 Swinehart; James M. Antipruritic composition
US5968969A (en) * 1996-08-21 1999-10-19 Pfizer Inc Stable, long acting salts of carboxamides for the treatment of joint disease
US5993836A (en) * 1998-04-28 1999-11-30 Castillo; James G. Topical anesthetic formulation
US5996579A (en) * 1998-06-26 1999-12-07 Coates; Michael R. Bag-valve-mask resuscitator attachment
US6008256A (en) * 1995-08-28 1999-12-28 Showa Yakuhin Kako Co., Ltd. Composition for local anesthesia
US6029863A (en) * 1998-10-05 2000-02-29 Ogram; Karen Rescue device for bee attacks
US6117877A (en) * 1998-02-27 2000-09-12 Synchroneuron, Llc Method for treating painful conditions of the anal region and compositions therefor
US6133299A (en) * 1993-02-25 2000-10-17 Warner-Lambert Company Methods for treating neurodegenerative diseases and disorders using N-(2,6-disubstituted aromatic)-N'-pyridinyl ureas and other anticonvulsant compounds
US6187294B1 (en) * 1999-06-10 2001-02-13 Russell Anthony Penner Topical anesthetic prophylaxis composition and the method for use thereof in scaling and polishing teeth
US6194455B1 (en) * 1999-05-28 2001-02-27 Marie Madeline Wharton Topical medicament for treating skin ulcers
US6235298B1 (en) * 1999-10-22 2001-05-22 Unilever Home & Personal Care Usa Phase stable multiple emulsion compositions
US6295469B1 (en) * 1997-11-14 2001-09-25 Alza Corporation Formulation for electrically assisted delivery of lidocaine and epinephrine
US6299902B1 (en) * 1999-05-19 2001-10-09 The University Of Georgia Research Foundation, Inc. Enhanced transdermal anesthesia of local anesthetic agents
US6350781B1 (en) * 1994-01-14 2002-02-26 Lee Shahinia, Jr. Method and analgesic preparations for sustained and extended corneal analgesia with subanesthetic concentrations of lidocaine
US6355705B1 (en) * 1997-02-07 2002-03-12 Queen's University At Kingston Anaesthetic bone cement
US6364899B1 (en) * 1998-01-23 2002-04-02 Innercool Therapies, Inc. Heat pipe nerve cooler
US6365590B1 (en) * 1998-05-26 2002-04-02 Saint Louis University Compounds, compositions and methods for treating erectile dysfunction
US6372786B2 (en) * 1999-05-28 2002-04-16 Marie Madeline Wharton Composition containing sucrafate and a topical anesthetic for humans and animals and method of use thereof
US6428564B1 (en) * 1999-11-30 2002-08-06 Patricia A. Ferguson Medical condition seat cushion system
US6429228B1 (en) * 1996-10-14 2002-08-06 Kowa Company, Ltd. Local anesthetic for external use
US6569839B1 (en) * 1998-09-16 2003-05-27 Mckay Douglas William Fast-acting pharmaceutical compositions and methods of use
US6620852B2 (en) * 2001-12-17 2003-09-16 Gerald Brogan Topical anesthetic
US6627620B1 (en) * 1998-12-18 2003-09-30 Per Julius Nielsen Composition set and kit for use in intraocular surgery
US6726913B1 (en) * 1999-10-15 2004-04-27 The Van Kampen Group, Inc. Treatment of dermal tumors, warts, and viral infections of the respiratory tract in humans using heat-killed P. acnes
US6743415B2 (en) * 2001-05-24 2004-06-01 Alexza Molecular Delivery Corporation Delivery of anti-migraine compounds through an inhalation route
US6838480B1 (en) * 1999-05-28 2005-01-04 Marie Madeline Wharton Composition containing sucrafate and a topical anesthetic for humans and animals and method of use thereof
US6861449B2 (en) * 2000-06-23 2005-03-01 Mayo Foundation For Medical Education And Research Method of treating neutrophil-related diseases with topical anesthetics
US7045549B2 (en) * 2001-11-08 2006-05-16 The Board Of Trustees Of The Leland Stanford Jr. University Treatment of symptoms associated with irritable bowel syndrome

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3783869A (en) * 1972-05-20 1974-01-08 L Schnipper Combined sanitary napkin and medicated bandage
US4261982A (en) * 1977-11-09 1981-04-14 The Procter & Gamble Company Therapeutic composition
US4588400A (en) * 1982-12-16 1986-05-13 Johnson & Johnson Products, Inc. Liquid loaded pad for medical applications
US5061689A (en) * 1986-12-24 1991-10-29 Bioderm, Inc. Zinc bacitracin containing wound dressing
US5804213A (en) * 1991-10-09 1998-09-08 Lectec Corporation Biologically active aqueous gel wound dressing
US5407670A (en) * 1993-01-28 1995-04-18 Shinault; Wanda K. Topical ointment for the treatment of epidermal trauma
DE60034667D1 (en) * 1999-02-01 2007-06-14 Dermal Res Lab Inc The pharmaceutical composition of complex carbohydrates and their application
US20020015726A1 (en) * 2000-06-30 2002-02-07 Scamilla Aledo Maria Aparecida De Carvalho Dressings and bandages comprising same
US6911196B2 (en) * 2002-07-31 2005-06-28 Samir I. Hamtini Topical medicament for treating nappy rash

Patent Citations (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372786B1 (en) *
US3968205A (en) * 1974-01-31 1976-07-06 J. Pfrimmer And Co. Infusion solution for the treatment of tachycardiac disturbances of heart rhythm and use thereof
US4005191A (en) * 1974-06-04 1977-01-25 Clark Mary G Topical ointment composition
US4069105A (en) * 1977-03-03 1978-01-17 Syva Company Lidocaine antigens and antibodies
US4181725A (en) * 1977-05-02 1980-01-01 The Regents Of The University Of Michigan Method for alleviating psoriasis
US4210670A (en) * 1977-07-06 1980-07-01 Astra Lakemedel Aktiebolag Antithrombotic agents
US4529601A (en) * 1977-12-01 1985-07-16 Astra Lakemedel Aktiebolag Local anesthetic mixture for topical application and method for obtaining local anesthesia
US4562060A (en) * 1977-12-01 1985-12-31 Astra Lakemedel Aktiebolag Local anesthetic mixture for topical application, process for its preparation, as well as method for obtaining local anesthesia
US4588744A (en) * 1978-09-19 1986-05-13 Mchugh John E Method of forming an aqueous solution of 3-3-Bis(p-hydroxyphenyl)-phthalide
US4618490A (en) * 1980-06-06 1986-10-21 Marco Peter T De Method of treatment of animal and human tissues damaged by burns and frank visible gangrene
US4891386A (en) * 1980-08-08 1990-01-02 Molteni & C. Dei F.Lli Alitti S.P.A. Lidocaine derivative and therapeutic compositions which contain it as principal active ingredient
US4623334A (en) * 1983-03-07 1986-11-18 Vanderbilt University Intravenous drug infusion apparatus
US4725442A (en) * 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US4622219A (en) * 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
US4650771A (en) * 1983-11-04 1987-03-17 Miles Laboratories, Inc. Immunogens, antibodies, labeled conjugates, and related derivatives for lidocaine and analogs thereof
US4628063A (en) * 1984-03-08 1986-12-09 Dana P. Brigham Antiviral pharmaceutical preparations and methods for their use
US4757088A (en) * 1984-03-08 1988-07-12 Dana P. Brigham Antiviral pharmaceutical preparations and methods for their use
US4914131A (en) * 1984-03-08 1990-04-03 Dana P. Brigham Antiviral pharmaceutical preparations and methods for their use
US4711906A (en) * 1984-12-21 1987-12-08 Merckle Gmbh Liquid diclofenac preparations
US4748022A (en) * 1985-03-25 1988-05-31 Busciglio John A Topical composition
US4963591A (en) * 1985-12-16 1990-10-16 Carter-Wallace Inc. Cosmetic compositions
US4851442A (en) * 1986-02-12 1989-07-25 W. Keith R. Watson Lidocaine hydrochloride, citric acid and dimethyl sulfoxide, solution, and formation thereof
US4938970A (en) * 1987-02-06 1990-07-03 Hustead Robert E Painless electrolyte solutions
US5387419A (en) * 1988-03-31 1995-02-07 The University Of Michigan System for controlled release of antiarrhythmic agents
US4866050A (en) * 1988-04-27 1989-09-12 Ben Amoz Daniel Ultrasonic transdermal application of steroid compositions
US5081157A (en) * 1988-05-02 1992-01-14 Zila Pharmaceuticals, Inc. Compositions and in situ methods for forming films on body tissue
US4997853A (en) * 1988-12-02 1991-03-05 Galenpharma, Inc. Method and compositions utilizing capsaicin as an external analgesic
USRE37727E1 (en) * 1989-03-17 2002-06-04 Hind Health Care Method for treating nerve injury pain associated with shingles
US5601838A (en) * 1989-03-17 1997-02-11 Hind Health Care, Inc. Method for treating pain associated with herpes-zoster and post-herpetic neuralgia
US5589180A (en) * 1989-03-17 1996-12-31 Hind Health Care, Inc. Method for treating nerve injury pain associated with shingles (herpes-zoster and post-herpetic neuralgia) by topical application of lidocaine
US5411738A (en) * 1989-03-17 1995-05-02 Hind Health Care, Inc. Method for treating nerve injury pain associated with shingles (herpes-zoster and post-herpetic neuralgia) by topical application of lidocaine
US5709869A (en) * 1989-03-17 1998-01-20 Hind Health Care, Inc. Method for treating nerve injury pain associated with shingles
US5331013A (en) * 1989-06-08 1994-07-19 Aktiebolaget Astra Method for the treatment of ulcerative proctitis and colitis
US5227165A (en) * 1989-11-13 1993-07-13 Nova Pharmaceutical Corporation Liposphere delivery systems for local anesthetics
US5417671A (en) * 1990-05-23 1995-05-23 Jackson; Richard R. Medical devices having local anesthetic effect and methods of their manufacture
US5331012A (en) * 1990-07-30 1994-07-19 Riddick Kenneth B Topical pharmaceutical preparation for fever blisters and other viral infections and method of use
US5886047A (en) * 1990-07-30 1999-03-23 Riddick; Kenneth B. Topical pharmaceutical preparation for fever blisters and other viral infections and method of use
US5112620A (en) * 1990-09-20 1992-05-12 Mikkur, Inc. Polyethylene glycol ointment for apthous ulcers
US5714165A (en) * 1990-09-20 1998-02-03 Mikkur, Inc. Bioadhesive polyethylene glycol ointment for medicaments
US5290775A (en) * 1990-12-19 1994-03-01 Board Of Trustees Operating Michigan State University Euthanasia compositions
US5827529A (en) * 1991-03-30 1998-10-27 Teikoku Seiyaku Kabushiki Kaisha External preparation for application to the skin containing lidocaine
US5298528A (en) * 1991-10-07 1994-03-29 Baker Cummins Dermatologicals, Inc. Insect repellent
US5510339A (en) * 1993-02-02 1996-04-23 Mayo Foundation For Medical Education And Research Method for the treatment of bronchial asthma by administration of topical anesthetics
US5631267A (en) * 1993-02-02 1997-05-20 Mayo Foundation For Medical Education & Research Method for the treatment of eosinophil-associated diseases by administration of topical anesthetics
US6133299A (en) * 1993-02-25 2000-10-17 Warner-Lambert Company Methods for treating neurodegenerative diseases and disorders using N-(2,6-disubstituted aromatic)-N'-pyridinyl ureas and other anticonvulsant compounds
US5679325A (en) * 1993-03-29 1997-10-21 Henry; Richard A. Lidocaine aerosol anaesthetic
US5593661A (en) * 1993-03-29 1997-01-14 Henry; Richard A. Lidocaine aerosol anaesthetic
US5330452A (en) * 1993-06-01 1994-07-19 Zook Gerald P Topical medicating device
US5415866A (en) * 1993-07-12 1995-05-16 Zook; Gerald P. Topical drug delivery system
US5480658A (en) * 1993-07-23 1996-01-02 Melman; Steven A. Ear and skin cleanser
US5405376A (en) * 1993-08-27 1995-04-11 Medtronic, Inc. Method and apparatus for ablation
US5810786A (en) * 1993-09-24 1998-09-22 Richard R. Jackson Tissue-numbing anesthetic articles
US5540669A (en) * 1993-09-30 1996-07-30 Becton, Dickinson And Company Iontophoretic drug delivery system and method for using same
US5420124A (en) * 1994-01-12 1995-05-30 Kim; Young S. Stable, painless piroxicam potassium injectable composition
US6350781B1 (en) * 1994-01-14 2002-02-26 Lee Shahinia, Jr. Method and analgesic preparations for sustained and extended corneal analgesia with subanesthetic concentrations of lidocaine
US5558914A (en) * 1994-04-11 1996-09-24 Water-Jel Technologies, Inc. Water-based formulation for the treatment of sunburn
US5589156A (en) * 1994-05-02 1996-12-31 Henry; Richard A. Prilocaine and hydrofluourocarbon aerosol preparations
US5453445A (en) * 1994-05-02 1995-09-26 Henry; Richard A. Lidocaine-phenylephrine aerosol preparation
US5534242A (en) * 1994-05-02 1996-07-09 Henry; Richard A. Lidocaine-vasoconstrictor aerosol preparation
US5504116A (en) * 1994-05-26 1996-04-02 Research Foundation Of State University Of New York Lidocaine for the management of preterm labor
US5630843A (en) * 1994-06-30 1997-05-20 Rosenberg; Paul H. Double chamber tissue expander
US5585398A (en) * 1994-07-15 1996-12-17 Ernst; Amy A. Topical anesthetic comprising lidocaine, adrenaline, and tetracaine, and its method of use
US5942543A (en) * 1994-07-15 1999-08-24 Ernst; Amy A. Topical anesthetic comprising lidocaine, adrenaline, and tetracaine, and its method of use
US5516808A (en) * 1994-10-27 1996-05-14 Sawaya; Assad S. Topical cellulose pharmaceutical formulation
US6008256A (en) * 1995-08-28 1999-12-28 Showa Yakuhin Kako Co., Ltd. Composition for local anesthesia
US5898035A (en) * 1995-08-29 1999-04-27 New York Medical College Formulations of haloalkylamines and local anesthetic and methods for the treatment of reflex sympathetic dystrophy (RSD)
US5762945A (en) * 1996-04-05 1998-06-09 Ashley; Eline Composition and method for treating diaper rash
US5698227A (en) * 1996-07-23 1997-12-16 Rivlin; Daniel Compositions comprising lidocaine and emu oil and methods of use thereof
US5968969A (en) * 1996-08-21 1999-10-19 Pfizer Inc Stable, long acting salts of carboxamides for the treatment of joint disease
US5707645A (en) * 1996-09-10 1998-01-13 Wierson; Mark Hemorrhoidal ice-treatment device
US6429228B1 (en) * 1996-10-14 2002-08-06 Kowa Company, Ltd. Local anesthetic for external use
US6355705B1 (en) * 1997-02-07 2002-03-12 Queen's University At Kingston Anaesthetic bone cement
US5837713A (en) * 1997-02-26 1998-11-17 Mayo Foundation For Medical Education And Research Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids
US5961997A (en) * 1997-03-25 1999-10-05 Swinehart; James M. Antipruritic composition
US5762063A (en) * 1997-05-21 1998-06-09 Coates; Michael R. Bag-valve-mask resuscitator attachment having syringe and nebulizer injection ports
US5891919A (en) * 1997-09-19 1999-04-06 Burlington Bio-Medical & Scientific Corp. Denatonium capsaicinate and methods of producing the same
US6295469B1 (en) * 1997-11-14 2001-09-25 Alza Corporation Formulation for electrically assisted delivery of lidocaine and epinephrine
US6364899B1 (en) * 1998-01-23 2002-04-02 Innercool Therapies, Inc. Heat pipe nerve cooler
US5955112A (en) * 1998-02-11 1999-09-21 Kaplan; Jeffrey Non-stinging styptic pencil
US6159944A (en) * 1998-02-27 2000-12-12 Synchroneuron, Llc Method for treating painful conditions of the anal region and compositions therefor
US6117877A (en) * 1998-02-27 2000-09-12 Synchroneuron, Llc Method for treating painful conditions of the anal region and compositions therefor
US5993836A (en) * 1998-04-28 1999-11-30 Castillo; James G. Topical anesthetic formulation
US6365590B1 (en) * 1998-05-26 2002-04-02 Saint Louis University Compounds, compositions and methods for treating erectile dysfunction
US5996579A (en) * 1998-06-26 1999-12-07 Coates; Michael R. Bag-valve-mask resuscitator attachment
US6569839B1 (en) * 1998-09-16 2003-05-27 Mckay Douglas William Fast-acting pharmaceutical compositions and methods of use
US6029863A (en) * 1998-10-05 2000-02-29 Ogram; Karen Rescue device for bee attacks
US6627620B1 (en) * 1998-12-18 2003-09-30 Per Julius Nielsen Composition set and kit for use in intraocular surgery
US6299902B1 (en) * 1999-05-19 2001-10-09 The University Of Georgia Research Foundation, Inc. Enhanced transdermal anesthesia of local anesthetic agents
US6194455B1 (en) * 1999-05-28 2001-02-27 Marie Madeline Wharton Topical medicament for treating skin ulcers
US6838480B1 (en) * 1999-05-28 2005-01-04 Marie Madeline Wharton Composition containing sucrafate and a topical anesthetic for humans and animals and method of use thereof
US6372786B2 (en) * 1999-05-28 2002-04-16 Marie Madeline Wharton Composition containing sucrafate and a topical anesthetic for humans and animals and method of use thereof
US6187294B1 (en) * 1999-06-10 2001-02-13 Russell Anthony Penner Topical anesthetic prophylaxis composition and the method for use thereof in scaling and polishing teeth
US6726913B1 (en) * 1999-10-15 2004-04-27 The Van Kampen Group, Inc. Treatment of dermal tumors, warts, and viral infections of the respiratory tract in humans using heat-killed P. acnes
US6235298B1 (en) * 1999-10-22 2001-05-22 Unilever Home & Personal Care Usa Phase stable multiple emulsion compositions
US6428564B1 (en) * 1999-11-30 2002-08-06 Patricia A. Ferguson Medical condition seat cushion system
US6861449B2 (en) * 2000-06-23 2005-03-01 Mayo Foundation For Medical Education And Research Method of treating neutrophil-related diseases with topical anesthetics
US7008615B2 (en) * 2001-05-24 2006-03-07 Alexza Pharmaceuticals, Inc. Delivery of anti-migraine compounds through an inhalation route
US6743415B2 (en) * 2001-05-24 2004-06-01 Alexza Molecular Delivery Corporation Delivery of anti-migraine compounds through an inhalation route
US7045549B2 (en) * 2001-11-08 2006-05-16 The Board Of Trustees Of The Leland Stanford Jr. University Treatment of symptoms associated with irritable bowel syndrome
US6620852B2 (en) * 2001-12-17 2003-09-16 Gerald Brogan Topical anesthetic

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050159477A1 (en) * 2002-07-25 2005-07-21 Chemagis Ltd Stable amorphous calcium pseudomonate and processes for the preparation thereof
US20070213688A1 (en) * 2003-05-21 2007-09-13 Klein Jeffrey A Infiltration cannula
US8105310B2 (en) 2003-05-21 2012-01-31 Klein Jeffrey A Infiltration cannula
US9623030B2 (en) 2004-06-25 2017-04-18 Jeffrey Alan KLEIN Tumescent antibiotic solution
US20080206371A1 (en) * 2007-02-22 2008-08-28 Healing Skin Llc Novel burn treatment composition
WO2009027823A2 (en) * 2007-08-29 2009-03-05 Ramirez D'onofrio, Alvaro D. Pharmaceutical composition for selective stimulation of wound healing processes, dermal-epidermal normal tissular trophism processes, its preparation and application.
WO2009027823A3 (en) * 2007-08-29 2009-04-23 Ramirez D Onofrio Alvaro D Pharmaceutical composition for selective stimulation of wound healing processes, dermal-epidermal normal tissular trophism processes, its preparation and application.
USRE46397E1 (en) 2007-11-07 2017-05-09 Svip5 Llc Slow release of organic salts of local anesthetics for pain relief
US20100233271A1 (en) * 2007-11-07 2010-09-16 Sawan Samuel P Slow release of organic salts of local anesthetics for pain relief
US8920843B2 (en) 2007-11-07 2014-12-30 Svip5 Llc Slow release of organic salts of local anesthetics for pain relief
US20110091538A1 (en) * 2008-06-17 2011-04-21 Z.H.T. Engineering Equipment And Technologies Ltd. Polymer adapted to release bioactive agents in vivo, pharmaceutical composition and method of preparation thereof
WO2010013204A1 (en) * 2008-07-29 2010-02-04 Luisa Gennero Composition for regenerating senescent cutaneous and sub-cutaneous tissue, products and uses thereof
US8957060B2 (en) 2009-11-30 2015-02-17 Jeffrey Alan KLEIN Tumescent antibiotic solution
US20140065119A1 (en) * 2010-11-10 2014-03-06 The University Of Western Ontario Methods and compositions comprising cyclic analogues of histatin 5 for treating wounds
EP3164139A4 (en) * 2014-07-01 2017-05-10 Enrique Chacon Topical compositions and methods for treating wounds
US9592280B2 (en) * 2014-10-10 2017-03-14 Rochal Industries Llc Compositions and kits for enzymatic debridement and methods of using the same
RU2641095C1 (en) * 2017-04-11 2018-01-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации Agent for pyoinflammatory processes in soft tissues and mucous membranes

Also Published As

Publication number Publication date Type
US7728188B2 (en) 2010-06-01 grant
US20070104770A1 (en) 2007-05-10 application
US20070110797A1 (en) 2007-05-17 application

Similar Documents

Publication Publication Date Title
Eaglstein Moist wound healing with occlusive dressings: a clinical focus
Cho et al. Dressing the part
O'meara et al. Systematic review of antimicrobial agents used for chronic wounds
US3969498A (en) Dressing and method for treating a wound
Ovington Advances in wound dressings
US6706279B1 (en) Wound dressing
Stashak et al. Update on wound dressings: indications and best use
US6458380B1 (en) Dressing and preparation delivery system
Simon et al. Medical honey for wound care—still the ‘latest resort’?
Eaglstein et al. Chronic wounds
EP1159972A2 (en) Anti-microbial dressing using metallic compounds
Atiyeh et al. Management of acute and chronic open wounds: the importance of moist environment in optimal wound healing
Hanna et al. A review of wound healing and wound dressing products
Molan et al. Clinical usage of honey as a wound dressing: an update
US6956144B2 (en) Honey based wound dressing
US20060127437A1 (en) Semisolid system and combination semisolid, multiparticulate system for sealing tissues and/or controlling biological fluids
US20020061329A1 (en) Wound dressing and drug delivery system
US5902600A (en) Hydrogel polymer wound dressing
Weller et al. Wound dressings update
US3812252A (en) Method of treating wounds with a medicinal dressing
Seaman Dressing selection in chronic wound management
US5762955A (en) Method for application and maintenance of medication on body tissue
Korting et al. Management of minor acute cutaneous wounds: importance of wound healing in a moist environment
Thomas Alginate dressings in surgery and wound management: Part 2
US20020172709A1 (en) Medical dressing comprising an antimicrobial silver compound and a method for enhancing wound healing